Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer
/in International Publications, Newcastle Disease Virus /von 2017-07-15 / Cancer Immunol. Immunother. 2017 Oct;66(10):1249-1264Evaluation of the oncolytic potential of RB Mukteshwar vaccine strain of Newcastle disease virus (NDV) in a colon cancer cell line (SW-620)
/in Colorectal Cancer, International Publications, Newcastle Disease Virus /von 2017-06-03 / Arch. Virol. 2017 Sep;162(9):2705-2713Oncolytic Viruses in Cancer Treatment: A Review
/in International Publications, Newcastle Disease Virus /von 2017-06-01 / JAMA Oncol 2017 Jun;3(6):841-849Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease
/in International Publications, Newcastle Disease Virus, Urothelial Carcinoma /von 2017-06-01 / Clin Adv Hematol Oncol 2017 Jun;15(6):466-477Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
/in International Publications, Newcastle Disease Virus /von 2017-05-23 / Cancer Res. 2017 08;77(15):4146-4157Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2017-05-20 / Int J Mol Sci 2017 May;18(5)Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives
/in International Publications, Newcastle Disease Virus /von 2017-05-15 / Front Immunol 2017;8:555Current status of clinical trials assessing oncolytic virus therapy for urological cancers
/in Hypernephroma, International Publications, Newcastle Disease Virus, Prostate Cancer, Urothelial Carcinoma /von 2017-03-21 / Int. J. Urol. 2017 05;24(5):342-351Immune and viral therapies for malignant primary brain tumors
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus /von 2017-03-05 / Expert Opin Biol Ther 2017 04;17(4):457-474
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de